These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11181764)

  • 21. Granulocyte-macrophage colony stimulating factor prior to chemotherapy for advanced epithelial ovarian cancer.
    Guner H; Oktem M; Dilek TU
    Int J Gynaecol Obstet; 2003 Dec; 83(3):317-8. PubMed ID: 14643049
    [No Abstract]   [Full Text] [Related]  

  • 22. A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer.
    Neill HB; Miller AA; Clamon GH; Perry MC; Crawford J; Green MR
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-130-S12-134. PubMed ID: 9331137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Which chemotherapy for diffuse forms of small-cell cancers?].
    Pujol JL; Quantin X; Carestia L; Guyot V; Khial F
    Rev Mal Respir; 1999 Jan; 16 Suppl 3():S149-55. PubMed ID: 10088297
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
    J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of colony stimulating factors in small cell lung cancer: why the question is still unsolved.
    Trillet-Lenoir V; Piedbois P; Buyse M
    Lung Cancer; 2002 Aug; 37(2):125-6. PubMed ID: 12140133
    [No Abstract]   [Full Text] [Related]  

  • 26. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Herbst R; Leong T; Lynch C; Kwiatkowski DJ; Carey RW; Grossbard ML; Skarin AT
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
    Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
    Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer.
    Pirker R; Ulsperger E; Messner J; Aigner K; Forstner B; Bacon P; Easton V; Skacel T
    Lung; 2006; 184(5):279-85. PubMed ID: 17235728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
    Leyvraz S; Perey L; Rosti G; Lange A; Pampallona S; Peters R; Humblet Y; Bosquée L; Pasini F; Marangolo M
    J Clin Oncol; 1999 Nov; 17(11):3531-9. PubMed ID: 10550151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis.
    Berghmans T; Paesmans M; Lafitte JJ; Mascaux C; Meert AP; Sculier JP
    Lung Cancer; 2002 Aug; 37(2):115-23. PubMed ID: 12140132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
    Zhou C; Huang Y; Wang D; An C; Zhou F; Li Y; Chen G; Wu C; He J; Wu G; Song X; Gao J; Liu W; Li B; Shi J; Huang C; Yu J; Feng J; Yue H; Shi M; Xia J
    Clin Lung Cancer; 2016 Mar; 17(2):119-27. PubMed ID: 26781346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re: A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer.
    Buyse M; Thirion P; Carlson RW; Burzykowski T; Molenberghs G; Piedbois P;
    J Natl Cancer Inst; 2001 Mar; 93(5):399-401. PubMed ID: 11238707
    [No Abstract]   [Full Text] [Related]  

  • 34. Experience with GM-CSF in the treatment of solid tumors.
    Wolf M; Havemann K
    Infection; 1992; 20 Suppl 2():S111-5. PubMed ID: 1337337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined-modality therapy for unresectable, stage III non-small-cell lung cancer--caveat emptor or caveat venditor?
    Johnson DH
    J Natl Cancer Inst; 1996 Sep; 88(17):1175-7. PubMed ID: 8780621
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in chemotherapy for lung cancer.
    Saijo N; Eguchi K; Etou H; Miyachi S; Morinari H; Nakada K; Noda K; Ohkuni Y; Watanabe K; Yamada Y
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):54-8. PubMed ID: 7512277
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
    Asakuma M; Yamamoto M; Wada M; Ryuge S; Katono K; Yokoba M; Fukui T; Takakura A; Otani S; Maki S; Igawa S; Yanaihara T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Masuda N
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1529-36. PubMed ID: 22415148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose chemo-radiotherapy cycles for LD small cell lung cancer patients using G-CSF and blood stem cells.
    Humblet Y; Bosquée L; Weynants P; Symann M
    Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S36-9. PubMed ID: 8899169
    [No Abstract]   [Full Text] [Related]  

  • 39. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study.
    Bunn PA; Kelly KL
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):54-8; discussion 59-60. PubMed ID: 7481862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.